 Regional chemotherapy continuous intravesical infusion doxorubicin treatment muscle invasive transitional cell bladder carcinoma rat model animal models invasive transitional cell bladder carcinoma continuous infusion intravesical drug delivery urothelial toxicity antineoplastic efficacy continuous intravesical infusion doxorubicin DOX Dose-response toxicity experiments histologic changes rat urinary bladder urothelial exposure different urinary levels DOX function duration drug infusion Systemic local drug absorption DOX levels serum bladder lymph nodes intervals drug administration vitro chemosensitivity assays tumor sensitivity DOX Treatment studies impact continuous infusion DOX days tumor implantation discernable changes normal urothelium bladders animals continuous intravesicle DOX mean urinary concentrations micrograms./ml micrograms./ml micrograms./ml periods days Serum drug concentrations non-significant upward trend start therapy Significant increases tissue DOX levels bladder lymph nodes chemotherapy days Mean tissue DOX concentrations bladder lymph nodes vitro sensitivity DOX-treated tumor-bearing animals mean tumor volume standard deviation gm gm average tumor volume gm gm control group Continuous infusion intraluminal chemotherapy clear cytoreductive effect minimal local toxicity model Drug tissue levels regional lymphatic drainage fields bladder wall Further study approach bladder-sparing alternative invasive disease